Compounds, composition, methods, targets for cancer therapy

Abstract

This invention points to biological molecules and/or sequences that can be used as target for designing drug for treating cancer. This invention also points to biological sequences that can be used to target those molecules as a mean to treat cancer.

What is claimed: 
     
         1 . Biological molecules of Targets used for designing anticancer drugs are comprising but not limited for
 a) Polynucleotide sequences   b) Polypeptide sequences   which, when been inhibited in expression levels and/or inactivated functionally, sensitize cancer cells to chemotherapeutic drug treatments, hereby, be used as target for developing anticancer drugs.   
     
     
         2 . According to  claim 1  Biological molecular targets for anticancer drug development wherein said polynucleotide sequences comprising
 i. a polynucleotide of (SEQ ID Nos: 2, 3, 4, 5, 14) 
 ii. a polynucleotide encoding a polypeptide of (SEQ ID Nos: 6, 7, 8, 9, 15) 
 iii. a polynucleotide which is a variant of (SEQ ID NoS: 2, 3, 4, 5, 14) 
 iv. a polynucleotide which is an allelic variant of (SEQ ID NoS: 2, 3, 4, 5, 14) 
 v. a polynucleotide which encodes a species homologue of the (SEQ ID NoS: 2, 3, 4, 5, 14) 
 
     
     
         3 . According to  claim 1  Biological molecular targets for anticancer drug development wherein said polypeptide sequences comprising
 a. polypeptide of SEQ ID NoS:: 6, 7, 8, 9, 15 
 b. a polypeptide domain of SEQ ID NoS:: 6, 7, 8, 9, 15 
 c. a polypeptide epitope of SEQ ID NoS:: 6, 7, 8, 9, 15 
 d. a full length protein of SEQ ID NoS:: 6, 7, 8, 9, 15 
 e. a variant of SEQ ID NoS:: 6, 7, 8, 9, 15 
 f. an allelic variant of SEQ ID NoS:: 6, 7, 8, 9, 15 
 g. a species homologue of SEQ ID NoS:: 6, 7, 8, 9, 15 
 
     
     
         4 . According to  claim 1 , the anticancer treatment target that can be targeted by the molecules that are capable of interfering, affecting or inhibiting the expression levels and/or interfering, affecting or inhibiting the functional activities of the targeted molecules or inactivating the target molecules functionally, to sensitize cancer cells to chemotherapeutic drug treatments comprising, but do not limited to
 a) the nucleotide sequences, synthetic, not synthetic, modified or not modified nucleotide molecules that are capable of being complemented to at least one of the sequence of sequences #2, #3, #4, #5, #14;   b) the nucleotide sequences, synthetic, not synthetic, modified or not modified nucleotide molecules that are capable of being complemented to at least one of the sequence of sequences #2, #3, #4, #5, #14 under strictly conditions;   c) the biological molecules that are capable of binding to, or altering, or interfering with, or blocking, or inhibiting the expression levels and/or functional activities of at least one of the peptide sequence with the sequence # of #6, #7, #8, #9 and/or #15 comprising polypeptides, proteins, antibodies, and antibody fragments;   d) Small molecule compounds that are capable of binding to, or altering or interfering with, or blocking, or inhibiting the expression levels and/or functional activities of at least one of the peptide sequence with the sequence # of #6, #7, #8, #9 and/or #15;   
     
     
         5 . According to  claim 4   ! ∘, means for binding to the molecules, or altering or interfering with, or blocking, or inhibiting the expression levels and/or functional activities of at least one of the of the said genes and gene products comprising
 a. synthetic or non synthetic polynucleotide, 
 b. modified or not modified 
 c. dominant negative DNA sequences, 
 d. DNA oligos, modified or not modified 
 e. PNAs 
 f. siRNAs 
 g. anti-sense RNAs 
 h. shRNAs
 i. polypeptides, modified or not modified 
 
 i. antibodies 
 j. antibody fragments 
 k. polypeptides 
 l. organic or inorganic molecules 
 m. small molecule antagonists 
 
     
     
         6 . synthetic polynucleotide further selected from the group of siRNA that were capable of altering, interfering, suppressing the expression levels and inhibiting/interfering the functional activities of the gene products of sequence comprising
 a. TPCR6 (SEQ ID NO:2), and/or   b. SH3PXD2B(SEQ ID NO:3), and/or   c. MAGI3(SEQ ID NO:4), and/or   d. TMEM182(SEQ ID NO:5), and/or   e. C6orf108(SEQ ID N0:14), and/or   f. siRNA#1 (SEQ ID N0:10), and/or   g. siRNA#2 (SEQ ID NO:11), and/or   h. siRNA#3 (SEQ ID NO:12).